These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30289642)

  • 1. [Atherogenesis in human - clinical aspects of circulating immune complexes].
    Babintseva YD; Sergeeva AM; Karagodin VP; Orekhov AN
    Klin Med (Mosk); 2016; 94(5):325-32. PubMed ID: 30289642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value.
    Sobenin IA; Salonen JT; Zhelankin AV; Melnichenko AA; Kaikkonen J; Bobryshev YV; Orekhov AN
    Biomed Res Int; 2014; 2014():205697. PubMed ID: 25054132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies against low-density lipoprotein and atherogenic potential of blood.
    Kacharava AG; Tertov VV; Orekhov AN
    Ann Med; 1993 Dec; 25(6):551-5. PubMed ID: 8292305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of low density lipoprotein isolated from circulating immune complexes.
    Tertov VV; Sobenin IA; Orekhov AN; Jaakkola O; Solakivi T; Nikkari T
    Atherosclerosis; 1996 May; 122(2):191-9. PubMed ID: 8769682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis.
    Sobenin IA; Karagodin VP; Melnichenko AC; Bobryshev YV; Orekhov AN
    J Clin Immunol; 2013 Feb; 33(2):489-95. PubMed ID: 23073618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis.
    Summerhill VI; Grechko AV; Yet SF; Sobenin IA; Orekhov AN
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis.
    Tertov VV; Orekhov AN; Kacharava AG; Sobenin IA; Perova NV; Smirnov VN
    Exp Mol Pathol; 1990 Jun; 52(3):300-8. PubMed ID: 2369935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.
    Orekhov AN; Bobryshev YV; Sobenin IA; Melnichenko AA; Chistiakov DA
    Int J Mol Sci; 2014 Jul; 15(7):12807-41. PubMed ID: 25050779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta.
    Kabakov AE; Tertov VV; Saenko VA; Poverenny AM; Orekhov AN
    Clin Immunol Immunopathol; 1992 Jun; 63(3):214-20. PubMed ID: 1623641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibodies against modified low-density lipoproteins and their complexes in blood of patients with various manifestations of atherosclerosis].
    Belik IV; Ivantsova AA; Mamedova ZE; Denisenko AD
    Biomed Khim; 2016 May; 62(4):471-5. PubMed ID: 27563003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization.
    Tertov VV; Sobenin IA; Gabbasov ZA; Popov EG; Jaakkola O; Solakivi T; Nikkari T; Smirnov VN; Orekhov AN
    Lab Invest; 1992 Nov; 67(5):665-75. PubMed ID: 1434544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cholesterol-containing circulating immune complexes--a component of the blood serum in patients with ischemic heart disease that determines its atherogenic properties].
    Tertov VV; Kacharava AG; Saiadian KhS; Serebrennikov SG; Liakishev AA; Kozlov SG; Gratsianskiĭ NA; Rogova EM; Bocharova OI; Orekhov AN
    Kardiologiia; 1989 Aug; 29(8):35-8. PubMed ID: 2479794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atherogenic modification of low-density lipoproteins].
    Sukhorukov VN; Karagodin VP; Orekhov AN
    Biomed Khim; 2016 May; 62(4):391-402. PubMed ID: 27562992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein immune complexes as markers of atherosclerosis.
    Orekhov AN; Kalenich OS; Tertov VV; Novikov ID
    Int J Tissue React; 1991; 13(5):233-6. PubMed ID: 1806545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of anti-low density lipoprotein antibodies and circulating immune complexes in aged subjects.
    Szondy E; Lengyel E; Mezey Z; Füst G; Gerö S
    Mech Ageing Dev; 1985 Feb; 29(2):117-23. PubMed ID: 3974305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An alternative hypothesis of the pathogenesis of atherosclerosis].
    Bhakdi S
    Herz; 1998 May; 23(3):163-7. PubMed ID: 9646097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
    Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
    Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis.
    Lopes-Virella MF; Virella G
    J Atheroscler Thromb; 2013; 20(10):743-54. PubMed ID: 23965492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidized LDL and anti-oxLDL antibody levels in peripheral atherosclerotic disease.
    Andican G; Seven A; Uncu M; Cantaşdemir M; Numan F; Burçak G
    Scand J Clin Lab Invest; 2008; 68(6):473-8. PubMed ID: 18609113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Front line of oxidized lipoproteins: role of oxidized lipoproteins in atherogenesis and cardiovascular disease risk].
    Yoshida H
    Rinsho Byori; 2010 Jun; 58(6):622-30. PubMed ID: 20662275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.